Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Clementia nets $75.9mm via FOPO

Executive Summary

Clementia Pharmaceuticals Inc. netted $75.9mm through the follow-on public offering of 6.1mm common shares (including full exercise of the overallotment) at $13.25 each. The company will use the funds for clinical trials of palovarotene including the Phase III trial in fibrodysplasia ossificans progressiva (FOP), Phase II in multiple osteochondromas, and Phase I in dry eye disease; to prepare for the NDA filing of palovarotene for FOP in H2 2019; and for commercialization activities for palovarotene.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies